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Abstract
The serine peptidases of Trypanosoma brucei have been viewed as potential drug targets.
In particular, the S9 prolyl oligopeptidase subfamily is thought to be a good avenue for drug
discovery. This is based on the finding that some S9 peptidases are secreted and active in
the mammalian bloodstream, and that they are a class of enzyme against which drugs have
successfully been developed. We collated a list of all serine peptidases in T. brucei, identify-
ing 20 serine peptidase genes, of which nine are S9 peptidases. We screened all 20 serine
peptidases by RNAi to determine which, if any, are essential for bloodstream form T. brucei
survival. All S9 serine peptidases were dispensable for parasite survival in vitro, even when
pairs of similar genes, coding for oligopeptidase B or prolyl oligopeptidase, were targeted si-
multaneously. We also found no effect on parasite survival in an animal host when the S9
peptidases oligopeptidase B, prolyl oligopeptidase or dipeptidyl peptidase 8 were targeted.
The only serine peptidase to emerge from the RNAi screen as essential was a putative
type-I signal peptide peptidase (SPP1). This gene was essential for parasite survival both in
vitro and in vivo. The growth defect conferred by RNAi depletion of SPP1 was rescued by
expression of a functional peptidase from an RNAi resistant SPP1 gene. However, expres-
sion of catalytically inactive SPP1 was unable to rescue cells from the SPP1 depleted phe-
notype, demonstrating that SPP1 serine peptidase activity is necessary for T.
brucei survival.
Introduction
Human African Trypanosomiasis (HAT) is a disease of the developing world that is fatal if left
untreated. Following strong collaborative efforts to combat the disease the number of new
cases reported has dropped to 17,500 annually [1], although the actual case-load is likely to be
at least three times the reported figure. While the improved situation is encouraging, there is
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still a pressing need for new chemotherapies for HAT. The current set of 4 licenced drugs
(pentamidine, suramin, melarsoprol, and eflornithine) has problems with toxicity, mode of ad-
ministration, or efficacy. Moreover the reduction in HAT prevalence has raised concerns of
disease resurgence as complacency causes a withdrawal of interest and resources.
The publication of the genome of Trypanosome brucei [2] marked a leap forward in the
quest for novel drug targets against this parasite. A combination of this genomic data together
with systems to induce loss-of-function using RNA interference in T. brucei led to an explosion
of studies highlighting specific genes that are important for the parasite and are thus potential
drug targets, reviewed in [3]. Most recently, high throughput studies have screened large co-
horts of genes for potential drug targets, taking in an entire chromosome [4], a gene family [5]
or the entire genome [6].
We have undertaken an RNAi study in which we scrutinise a biochemically related set of
genes, the serine peptidases, as potential drug targets. The serine peptidases are deemed suit-
able drug target candidates as some appear to be important virulence factors in both T. brucei
and Trypanosoma cruzi [7–9]. Oligopeptidase B (OPB) is released in to the bloodstream from
both Trypanosoma evansi and T. brucei where, as there are no effective endogenous inhibitors,
it proteolytically inactivates host peptide hormones [10, 11]. In addition to their likely involve-
ment in host-parasite interactions, there is evidence suggesting that serine peptidases are drug
targets. Two classes of serine peptidase inhibitor have anti-trypanosomal activity against T.
brucei [12] and the currently used therapeutic drugs suramin, pentamidine and diminiazine in-
hibit T. brucei OPB. The mode of action of these drugs is not necessarily via serine peptidases,
and serine peptidases were not amongst the 28 genes linked to suramin action in a genome
scale RNAi screen [13]. Nevertheless, there is sufficient evidence that T. brucei serine pepti-
dases are worth investigating as potential drug targets. Importantly, peptidases are biochemi-
cally tractable and are likely to be druggable. Amongst the many examples of peptidases that
have been successfully developed as drug targets is the serine peptidase DPP IV. Human DPP
IV is the target of inhibitors which are licensed for the treatment of type 2 diabetes [14].
Here, we have conducted a medium-throughput investigation into potential novel drug tar-
gets, comprising all serine peptidases in T. brucei. From the 20 putative serine peptidases in T.
brucei we found only one that was essential for parasite survival, a putative type I-like
signal peptidase.
Materials and Methods
Ethics statement
All animal procedures were undertaken in adherence to experimental guidelines and proce-
dures approved by The Home Office of the UK government. All work was covered by Home
Office Project Licence PPL60/4442 entitled “Molecular Genetics of Trypanosomes and Leish-
mania". Mice were euthanised by carbon dioxide inhalation, in accordance with the Animals
(Scientific Procedures) Act 1986.
Bioinformatics
All T. brucei TREU 927 predicted protein sequences were downloaded from TriTrypDB. To
search for predicted serine peptidases based on overall sequence homology, these protein se-
quences were used in a BLASTP search against the MEROPS peptidase database [15]. This gen-
erated a list of 29 potential serine peptidases. Of these, 16 were already annotated as serine
peptidases in GeneDB at the time of searching. The remaining 13 sequences were used in a
BLASTP search for closest relatives in the non-redundant protein database. Of these, 10 were
found to be more closely related to other families of hydrolases, such as esterases and lipases,
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and therefore unlikely to be peptidases. Three sequences (Tb927.8.5760, Tb927.9.12980,
Tb927.6.1810), however, were found to have sequence homology with serine peptidases. To de-
termine whether these were active serine peptidases or pseudopeptidases, we searched for ac-
tive site residues. Serine peptidases possess a nucleophilic serine residue, which forms part of
the catalytic dyad or triad. The genes Tb927.8.5760 and Tb927.6.1810 code sequences contain-
ing the catalytic residues serine, aspartic acid, and histidine, the catalytic triad possessed by S9
family serine peptidases. So, based on sequence homology and the presence of the catalytic
triad, Tb927.8.5760 and Tb927.6.1810 appear to be S9 serine peptidases.
In addition to identifying unidentified serine peptidases, we also examined the 9 genes an-
notated as serine peptidases in GeneDB, but were not retrieved by the BLASTP search against
the MEROPS database. When individual protein sequences were used in a BLASTP search of
the MEROPS database, several of these sequences were found to be peptidases from families
other than the serine peptidase family, or unlikely to be peptidases at all (Tb927.5.1870,
Tb927.10.3520, Tb927.11.3870, Tb927.11.8350, Tb927.2.5980, Tb927.2.3030). The GeneDB an-
notation for these six genes has since been altered to remove them as putative serine peptidases.
Three other genes annotated as serine peptidases appear to code for pseudopeptidases, as they
bear sequence homology to the serine peptidase families S51 (Tb927.11.12610) and S54
(Tb927.9.8260 and Tb927.8.1810), yet lack the designated active site residues for that family.
Elsewhere, one predicted rhomboid-like gene (Tb927.2.2500) has been identified that contains
S54 family active site residues [16] and was added to the list of serine peptidases (Table 1).
Cell culture
The T. brucei bloodstream form 2T1 cell line [17] was a gift from David Horn (LSHTM, Lon-
don) and was cultured in HMI-11 (HMI-9 (Gibco), 10% v/v FCS (Gibco,10270), Penicillin
(20Uml-1)/Streptomycin (20 μgml-1) (Sigma)), as described previously [17]. Selective drugs
were used at the following concentrations where appropriate: 2 μgml-1 puromycin, 2.5 μgml-1
phleomycin (InvivoGen), 5 μgml-1 hygromycin B (Calbiochem) and 10 μgml-1 blasticidin
(InvivoGen).
Plasmid construction
An RNAi target fragment of 400–600 bp was identified for each gene using RNAit target selec-
tion software [18]. Target fragments were amplified from T. brucei genomic DNA with forward
and reverse primers including AttB1 and AttB2 sites respectively (S1 Table). The constructs
used for RNA interference were based on the tetracycline inducible stem loop RNAi vector
pRPAiSL[17]. The plasmid has been modified to incorporate two pairs of AttP1 and AttP2 se-
quences, in opposing directions, flanking the toxic ccdB gene [5]. Two copies of the AttB1/
AttB2 tagged RNAi target fragment were incorporated in opposing directions in to the plasmid
in a single reaction using BP recombinase. Recombination of the RNAi fragments in to the vec-
tor was tested using a ccdB susceptible strain of E. coli to grow the plasmid.
Recoded SPP1 was synthesised by Dundee Cell Products. The recoded SPPI sequence
(SPPIR) codes for the same amino acid sequence as SPPI but only shares 76.3% identity (S1
Fig.). All segments of identity between SPPI and SPPIR are less than 20 base pairs long. SPPIR
was inserted in to the plasmid pGL2243 using XbaI and BamHI restriction sites, generating
pGL2308. This plasmid is designed to constitutively express SPPI from the tubulin locus, with
the addition of a C-terminal 6x HA tag (Jones, NG, unpublished). To express catalytically inac-
tive SPPI, the active site serine (Ser84) was changed to glycine by mutating pGL2308, carrying
the coding sequence for SPP1, using site directed mutagenic PCR with oligonucleotides
OL4309 and OL4310, generating the plasmid pGL2319.
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Cell lines and transfection
RNAi plasmids (5μg) were digested with AscI to linearise the integration cassette, which was
then purified with a QiagenPCR purification kit, ethanol precipitated and resuspended in 10μl
sterile water. 2T1 cells were transfected using a Nucleofector instrument (Lonza), in the on the
X01 setting, using the Amaxa Human T cell Nucleofector kit (Lonza). Cells that had integrated
the RNAi cassette were selected using hygromycin (2.5μg ml-1). Clonal cell lines generated in
this step were then tested for puromycin sensitivity, and puromycin sensitive clones retained
for further analysis. To determine the RNAi phenotype, cells were induced with 1μg ml-1 tetra-
cycline at a cell density of 1 x 105ml-1 and counted at 24 hour intervals for 5 days. Two individ-
ual clonal cell lines were analysed for each target gene. For expression from recoded SPP1, 5μg
of pGL2308 or pGL2319 (inactive mutant) were digested with AscI, and transfected as for the
RNAi plasmids (above). Cells that had integrated the recoded SPP1 expression cassette were se-
lected for using blasticidin (10μgml-1). Blasticidin resistant clones were subjected to a second
round of selection with tetracycline to induce RNAi. Clones that survived 3 days in the pres-
ence of 1μgml-1 tetracycline were tested for expression of SPP1 by Western blot with an anti-
HA antibody (Roche).
Table 1. Comparison of serine peptidase RNAi screen with RIT-seq phenotypes.
Family Gene ID Gene name RIT-seq phenotype† RNAi cell line
phenotype
S8 Subtilisin Tb927.3.4230 subtilisin-like serine peptidase Normal in all Normal
Tb927.11.3780* subtilisin-like serine peptidase Abnormal in BSF 6d and
PCF
Normal
S9
Prolyloligopeptidase
Tb927.11.12850 oligopeptidase B Normal in all Normal
Tb927.10.8020 prolyl oligopeptidase, putative Normal in all Normal
Tb927.5.4300 prolyl oligopeptidase-like Normal in all Normal
Tb927.10.6940
*
dipeptidyl peptidase As for Tb927.10.6970 Normal
Tb927.10.6970
*
dipeptidyl peptidase Normal in all Normal
Tb927.7.4940 * oligopeptidase B-like Abnormal in BSF 3d and 6d Normal
Tb11.v5.0175 * oligopeptidase B-like As for Tb927.7.4940 Normal
Tb927.9.10970 BEM46-like Normal in all Normal
Tb927.1.4780 S9D serine peptidase Abnormal in diff BSF Normal
Tb927.8.5760 hypothetical protein Abnormal in BSF 6d Normal
Tb927.6.1810 hypothetical protein Normal in all Normal
S10 Carboxypeptidase Tb927.10.1030 serine carboxypeptidase III precursor Normal in all Normal
Tb927.10.1040 serine carboxypeptidase III precursor As for Tb927.10.1030 Normal
Tb927.10.1050 serine carboxypeptidase III precursor As for Tb927.10.1030 Normal
S26 Signal peptidase Tb927.10.4590 mitochondrial inner membrane signal
peptidase
Normal in all Normal
Tb927.5.3220 signal peptidase type I Normal in all Abnormal
S54 Rhomboid Tb927.2.2500 hypothetical protein Normal in all Normal
S59 Nucleoporin Tb927.11.980 nucleoporin Normal in all Normal
* Identical coding sequences
† 3d, 6d denote 3 and 6 days after induction of RNAi
doi:10.1371/journal.pone.0123241.t001
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Activity of DPP8 inhibitors
The following compounds that target human DPP8 and DPP9 (and in some cases DPP IV),
were synthesised as described previously: UAMC-00374, UAMC-00662 [19]; UAMC-00491
[20]; UAMC-00691, UAMC-00701, UAMC-00726 [21]; vildagliptin [22]; UAMC-0800 [23].
These were stored in DMSO at -20°C and diluted immediately prior to use such that the maxi-
mum DMSO concentration in the assay did not exceed 1%. The IC50 of inhibitory compounds
against recombinant TbDPP8 was determined using a fluorometric assay in a 96-well flat-
bottomed plate in 50 mM Tris/HCl pH 7.5, 100 mMNaCl. Compounds were doubly diluted to
give final concentrations ranging down from 100 μM and Tb-DPP8 was added to the assay at
the indicated concentrations. The hydrolysis of the fluorogenic substrate H-Gly-Pro-AMC
(Bachem) was measured on an EnVision plate reader using excitation and emission wave-
lengths of 355 nm ad 460 nm respectively. Fluorescence was plotted against compound concen-
tration and the IC50 values calculated using GraFit (Erithicus).
To test the effect of compounds on parasites, inhibitory compounds were doubly diluted in
HMI-11 from 250 μM (final inhibitor concentration) in a 96-well plate (Costar). Bloodstream
form T. brucei 427 was added at a density of 1 x 105 cells ml-1in 200 μl HMI-11 in a 96-well
plate. Parasites were incubated with compounds for 48 hours, after which 0.1 volumes of Ala-
mar Blue (0.49 mM resazurin in PBS) were added. After incubation for a further 24 hours, fluo-
rescence was read at λexcitation 485 nm and λemission 620 nm in an Envision Plate Reader (Perkin
Elmer). The EC50 was calculated using GraFit software.
Quantitative PCR
Total RNA was purified from 2–5 x 107 T. brucei cells using the RNeasy miniprep kit (Qiagen)
according to manufacturer’s instructions. Genomic DNA was removed with RQ1 DNaseI (Pro-
mega) and first strand cDNA synthesised using Superscript III (Invitrogen) according to man-
ufacturer’s instructions. Quantitative PCR was done with a 7500 Real-time PCR system
(Applied Biosystems) and the 25 μl reaction contained approximately 0.5 μg cDNA, 7.5 pmol
of each primer, and Sybr Green PCR Master Mix (Applied Biosystems). The primers used for
all real time PCR reactions are listed in S2 Table. The temperature cycling regime was as fol-
lows: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of (95°C for 15 sec and 60°C for 1
min). Relative quantification was done using the comparative Ct method (2-ΔΔCT) within the
7500 System SDS software.
In vivo RNAi
Groups of four ICR mice were infected with 5 x 105 T. brucei RNAi cells by intraperitoneal in-
jection. RNAi was induced in two mice from each group by giving mice water containing 0.2g/
L doxycycline with 5% sucrose. Parasitaemia was checked daily by diluting tail vein blood in
0.83% ammonium chloride and counting parasites using a haemocytometer.
Results
Identification of serine peptidases
We found 20 individual genes representing serine peptidases from six families in the T. brucei
genome (Table 1). Notably, representatives of the largest peptidase family, the S1 (chymotryp-
sin/trypsin) peptidases, are not found at all in T. brucei, nor any of the trypanosomatids [15].
The most abundant serine peptidase family in T.brucei is the S9 prolyl oligopeptidase-like fami-
ly (reviewed in [23]), with nine members present in the genome. This family includes oligopep-
tidaseB, a peptidase found only in plants, bacteria and kinetoplastids. There are three genes
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encoding oligopeptidase B like peptidases in T. brucei (Tb927.11.12850, Tb927.7.4940, and
Tb11.v5.0175), the latter two of which are identical gene sequences. There are also two identical
tandem copies of a dipeptidyl peptidase 8 like gene (Tb927.10.6940 and Tb927.10.6970), which
is also a member of the S9 family. Other S9 peptidases include two prolyl oligopeptidase-like
genes (Tb927.10.8020 and Tb927.5.4300), a BEM46 like gene (Tb927.9.10970), and a glutamyl
endopeptidase (Tb927.1.4780). In addition to these previously indentified S9 peptidases, we
identified two new S9 family members (Tb927.8.5760 and Tb927.6.1810) by performing a
BLAST search of the MEROPS peptidase database [15] using the entire T. brucei genome. The
genome also contains two subtilisin (S8 family) genes (Tb927.3.4230 and Tb11.02.1280), three
carboxypeptidase (S10 family) genes (Tb927.10.1030, Tb927.10.1040, Tb927.10.1050), two sig-
nal peptidase (S26 family) genes (Tb927.10.4590 and Tb927.5.3220), one nucleoporin (S59
family) gene (Tb11.03.0140) and one rhomboid (S54 family) gene (Tb927.2.2500). We also
identified four potential pseudopeptidases, which have sequence similarity but lack predicted
active site residues: an S9 BEM46-like pseudopeptidase (Tb927.9.12980), two S54 rhomboid-
like pseudopeptidases (Tb927.9.8260 and Tb927.8.1810) and an S51 dipeptidase E-like pseudo-
peptidase (Tb927.11.12610).
RNAi screen
To determine the parasite’s requirement for individual peptidases, RNAi was used to knock
down transcript levels. We chose to use an inducible stem loop RNAi vector, inserted at an op-
timised and tagged ribosomal locus [17] as this vector has been shown to have efficient and re-
producible knock down of target genes [24]. The stem loop vector pRPaiSL has been modified
to include AttP1 and AttP2 recombination sites, enabling higher throughput cloning of RNAi
target sequences [5]. After induction of RNAi with tetracycline, cell lines were monitored for
five days for any growth defects. RNAi knock-down of all peptidases except one
(Tb927.5.3220, a putative signal peptidase) had no effect on parasite growth (Fig. 1). Most ser-
ine peptidase genes were targeted individually, but some multi-target RNAi plasmids were de-
signed. The tandem array of carboxypeptidase genes (Tb927.10.1030, Tb927.10.1040 and
Tb927.10.50) share 84% identity, and so were targeted with a single RNAi fragment. There are
also highly similar genes amongst the S9 serine peptidases. The non-contiguous genes coding
for oligopeptidase B (OPB), (Tb927.11.12850), and OPB-like peptidases (Tb927.7.4940) share
40% identity, and may have similar activities and/or function. To overcome possible OPB/
OPB-like redundancy, a knock-down construct targeting both genes was designed. As there is
insufficient sequence identity to target both genes with a single RNAi fragment, a construct in-
corporating two tandem RNAi fragments was generated (pTL2078). Similarly there are two
prolyl oligopeptidase (POP)-like genes, Tb927.10.8020 and Tb927.5.4300, having 34% identity,
and these were simultaneously targeted with a dual RNAi construct (pTL2079).
The cell lines in which the OPB and OPB-like genes (Tb927.11.12850 and Tb927.7.4940/
Tb11.v5.0175) or the POP and POP-like genes (Tb927.10.8020 and Tb927.5.4300) were tar-
geted displayed no growth defect under RNAi. The non-essential nature of OPB seen in our
RNAi lines is supported by the observation elsewhere that OPB knock-out cells had no loss of
virulence [25].
To determine whether the correct gene was being targeted, we used quantitative PCR to
measure relative levels of transcript. In all cases bar one (Tb927.11.980—omitted from dataset),
there was a decrease in the amount of transcript 24 hours after RNAi induction, ranging from
20% to 90% depletion, with an average knock down of 60% (Fig. 1, inset). Antibodies against
two target serine peptidases—OPB (Tb927.11.12850) and DPP8 (Tb927.10.6940 and
Tb927.10.6970)—were available, and these were used to check targeted knock-down at the
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protein level. Significant knock down of both OPB and DPP8 was seen at 24 hours (Fig. 1 in-
sets), supporting the quantitative PCR data.
The S9 serine peptidases
While OPB/OPB-like and POP/POP-like peptidases appear dispensable for the parasite per se,
we investigated whether these peptidases might be involved in the host parasite interaction.
Both OPB and POP are present in the secretome of T. brucei gambiense [26] and have been
shown to be active in the plasma of infected rodents [7, 8], and could therefore influence the
course of infection via cleavage of host peptides in the bloodstream. To test this, ICR mice were
infected with RNAi cell lines targeting the two OPB/OPB-like genes (Tb927.11.12850 and
Fig 1. Effect of RNAi of serine peptidases on T. brucei cell growth in vitro. Two independent RNAi cell lines were induced with 1 μgml-1 tetracycline
(open symbols) or left untreated (filled symbols). Cells were counted every 24 hours, diluted down to 1 x 105 cells ml-1 and the cumulative cell number
calculated. Insets: Target transcript levels in RNAi cell lines. Insets (upper left): Total RNA was isolated from non-induced (solid bars) or tetracycline-induced
(striped bars) cells and used to make cDNA, which was used as a template in a real time PCR reaction using gene-specific primers (S2 Table). For cell lines
in which multiple genes with non-identical sequences were targeted, PCR results for each target are shown. Results from three technical replicates are
shown. Insets (lower right): For two targets, Western blots were done on lysates from control (-) or tetracycline induced (+) cells, using RNAi target protein-
specific antibody (upper panel) or α-EF1-α (lower panel).
doi:10.1371/journal.pone.0123241.g001
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Tb927.7.4940), or the two POP/POP-like genes (Tb927.10.8020 and Tb927.5.4300). Parasitae-
mia in infected animals was measured 24 and 48 hours after induction of RNAi (Fig. 2a and b).
At these time points, there was no significant difference between induced and uninduced RNAi
lines for either pair of peptidases. Animals were euthanised after this point, as parasiteamia lev-
els rose above the humane threshold of 1 x 108 cells ml-1. These results indicate that a reduction
in either OPB/OPB-like or POP/POP-like peptidases has no effect on the progression of infec-
tion in mice, either individually or in concert.
We further investigated the T. brucei dipeptidyl peptidase (DPP8) for two reasons. Firstly,
as a member of the S9 serine peptidase family, which includes putative virulence factors such
as POP and OPB, we hypothesised that DPP8 in the host bloodstream may affect virulence. In-
deed, the related human enzyme DPP IV is known to cleave, and thereby inactivate, circulating
chemokines [27]. Secondly, human DPP IV is the target of type-2 diabetes drugs setting a pre-
cedent for the drugability of this enzyme. We expressed the recombinant enzyme, and con-
firmed that it is a Pro-specific aminopeptidase, as it was able to cleave the peptide substrate
H-Gly-Pro-AMC, but not the N-terminally blocked Z-Gly-Pro-AMC (Fig. 3a). We used the
Fig 2. Effect of RNAi on T. brucei cell growth in vivo. ICR mice were inoculated with RNAi cell lines targeting the two OPB-like genes (a), two POP-like
genes (b), dipeptidyl peptidase-8 (c), or the type-I signal peptidase (d). Two mice in each experiment were left untreated (filled symbols) and two were given
doxycycline (open symbols) to induce RNAi. The arrow indicates doxycycline administration. Parasitaemia in infected mice was counted at the
times indicated.
doi:10.1371/journal.pone.0123241.g002
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recombinant DPP8 activity assay to test a panel of potential DPP8 inhibitors: one licensed dia-
betes drug, vildagliptin, and a series of compounds designed to target human DPP IV/8/9 en-
zymes [28] (Fig. 3b). T. brucei DPP8 was inhibited at 40–60 nM by UAMC00374,
UAMC00691 and vildagliptin (Fig. 3c). These molecules, along with data on their inhibitory
potency (IC50-values) against human DPP IV, DPP8/9, prolyl oligopeptidase, DPP II, and fi-
broblast activation protein (FAP) have been reported earlier [19–23]. The IC50 values for the
human enzyme that are presented here were determined under slightly different conditions to
those published earlier. This accounts for the slightly different, but nonetheless comparable
IC50-values.
Nevertheless, these compounds were relatively ineffective against the bloodstream form of
T. brucei, all having EC50 values greater than 25μM, suggesting that chemical depletion of
DPP8 is not detrimental to the parasite. The most effective trypanocidal compounds
(UAMC00701 and UAMC00726) were poor inhibitors of DPP8, further highlighting the lack
of correlation between trypanocidal activity and DPP8 inhibition. The poor trypanocidal activ-
ity of DPP IV inhibitors is consistent with the result from the RNAi screen showing no effect of
DPP8 knock down. In addition, RNAi of DPP8 in vivo caused no change in parasitaemia
Fig 3. Recombinant TbDPP8 activity and inhibition. (a) Rate of cleavage by TbDPP8 of H-Gly-Pro-AMC (grey bars) and Z-Gly-Pro-AMC (white bars). (b)
Structures of inhibitors used against TbDPP8. (c) Inhibitory activity of compounds against T. brucei DPP8, human DPP IV, human DPP8, and bloodstream
form T. brucei 427.
doi:10.1371/journal.pone.0123241.g003
An Essential Signal Peptide Peptidase from Trypanosoma brucei
PLOSONE | DOI:10.1371/journal.pone.0123241 March 27, 2015 9 / 15
(Fig. 2c) indicating that, even if DPP8 does have activity in the host bloodstream, this does not
affect the progression of infection.
Type I signal peptidase
While GeneDB lists the T. brucei type I signal peptidase (SPP1, Tb927.5.3220) as a member of
the E. coli-like S26A sub-family, we found it to be more similar to the animal type-I signal pep-
tidases (S26B sub-family), bearing 33% sequence identity to human SEC11c compared with
12% with E. coli SP-1. In addition, T. brucei SPP1 codes for a serine/histidine catalytic dyad, a
feature of S26B peptidases, rather than the serine/lysine dyad found in S26A peptidases [20].
As SPP1 appears to be the only serine peptidase that is necessary for T. brucei survival in
vitro, we examined more closely the effects of depleting this gene. Firstly, we tested whether the
loss of fitness of the parasites held true in vivo. Mice were inoculated with the SPP1 RNAi cell
line and RNAi induced with doxycycline. Parasitaemia in the doxycycline treated mice
dropped by 48 hours, and was undetectable by 72 hours (Fig. 2d). The kinetics of parasite de-
pletion under RNAi in vivo is similar to that seen in vitro.
We looked for evidence that the phenotype displayed in the SPP1 RNAi cell line was due to
off-target transcript depletion, bymeasuring the level of a mitochondrial signal peptidase
(mitSP, Tb927.10.4590) after induction of SPP1 RNAi. The mitSP gene bears 42% identity to
SPP1, yet should have insufficient local sequence similarity to be a target in the SPP1 RNAi cell
line. Quantitative PCR after RNAi of SPP1 showed that, despite significant (>80%) reduction
in SPP1 transcript, mitSP transcript was not depleted. Indeed, mitSP transcript increased by
over 50% (data not shown), possibly reflecting compensation for depletion of SPP1.
In order to verify that SPP1 knock-down was responsible for the loss of fitness in the RNAi
line, we attempted to rescue the SPP1 RNAi phenotype by expressing an RNAi-resistant
recoded SPP1 gene (SPP1R). SPP1R has insufficient sequence identity with the endogenous
SPP1 gene to be a target for the RNAi machinery and leads to constitutive expression of full
length SPP1. We were able to detect expression of SPP1R protein via its C-terminal HA tag
(Fig. 4a). When SPP1 RNAi was induced in this cell line, there was no growth defect (Fig. 4b),
indicating that these cells had been rescued from the detrimental RNAi phenotype (Fig. 4c) by
functional expression of SPP1. To verify that RNAi of endogenous SPP1 remained functional
in cells expressing SPP1R, we used quantitative PCR. Endogenous SPP1 transcript was reduced
by approximately 85% in tetracycline-induced cells, similar to knock-down levels seen in the
parental SPP1 RNAi line (Fig. 4d). This demonstrates that the normal phenotype in these cells
was due to the presence of functional SPP1, rather than the emergence of cells refractory to
RNAi. We next wanted to test whether the ability of the SPP1R gene to restore normal pheno-
type was due to its putative serine peptidase activity. The active site serine was mutated to gly-
cine, and the expression of mutated SPP1confirmed by Western blot (Fig. 4a). Cells expressing
catalytically inactive SPP1 displayed a growth defect when endogenous SPP1 was down-regu-
lated by RNAi (Fig. 4e), similar to that of the parental RNAi cell line (Fig. 4c).
With the aim of verifying the signal peptidase activity of T. brucei SPP1 we expressed and
purified recombinant forms of the protein in E. coli. A small amount of soluble recombinant
protein, lacking the predicted N-terminal transmembrane domain and carrying an N-terminal
MBP fusion, was purified (not shown). However, we were unable to detect peptidase activity
using a fluorogenic peptide substrate known to be cleaved by E. coli and P. falciparum signal
peptidases [29]. We also attempted to rescue E. coli strains which are conditionally deficient in
endogenous signal peptidase (LepB) [21], by expressing SPP1. Although expression of either
full length or truncated SPP1 was successfully induced under conditions of LepB repression,
this was insufficient to rescue the LepB deficient growth defect (not shown).
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Discussion
Technical developments, notably improved transfection efficiency [30], have expanded the
scope of RNAi in T. brucei, to the extent that genome-wide RNAi screens can be carried out [6,
31]. A deficiency with screens on that scale is that, when the measured output is loss of fitness,
clonal cell lines are not isolated from the genome-wide pool. Instead, regeneration of individual
RNAi cell lines must be carried out to confirm the importance to viability of the identified
genes. By exploiting recent developments in RNAi in T. brucei [5, 17] we have been able to
screen the complete set of serine peptidases in T. brucei, followed up by qPCR validation of in-
dividual clones. In addition, we have been able to extend analysis of potentially interesting tar-
gets to an in vivomodel.
We report that there are 20 serine peptidase genes in T. brucei, which represent 18 unique
coding sequences. While only one gene, SPP1, emerged from our screen as essential, compari-
son with a genome-wide RNAi screen [6], showed that SPP1 was not revealed by the RIT-seq
method to be essential (Table 1). In contrast to the genome screen, we were able to validate
each of the RNAi cell lines using quantitative PCR, and subsequently follow up our in vitro
data with in vivo experiments. One explanation for the failure of RIT-seq to detect SPP1 is the
Fig 4. Rescue of SPP1RNAi growth defect by expression of recoded SPPI. (a) Expression of recoded HA-tagged SPP1 detected byWestern blot. Cell
lysates from RNAi cell line (-), the RNAi cell line expressing SPP1 from the recoded gene (SPP1R), or the RNAi cell line expressing inactive SPP1 from a
recodedgene (SPP1R,I) were probed with anti-HA antibody (Roche). Detection of EF-1α was used as a loading control. (b, c and e) Parasite growth was
measured in cell lines after inducing SPP1 RNAi with tetracycline (open squares) or without treatment (closed squares) in the SPP1RNAi cell line expressing
SPP1 from: the recoded gene SPP1R (b), the parental SPP1RNAi cell line (c), or the RNAi cell line expressing inactive SPP1 from a recoded gene, SPP1R,I
(e). (d) Quantitative PCR showing relative quantification (RQ) of endogenous SPP1 transcript in the RNAi cell line expressing active SPP1 from the SPP1R
gene either without induction (control, black bars) or after induction by tetracycline (+ Tet, white bars).
doi:10.1371/journal.pone.0123241.g004
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relatively small gene size. At 627bp, SPP1 is likely to be under-represented in the RNAi library
(which reported an average of>5 targets/CDS), and is possibly more likely to fall below the
threshold of significant difference between induced and uninduced cells. Results for three
other serine peptidases in our screen do not correlate with the RIT-seq data. One of these is the
OPB-like gene (Tb927.7.4940) which displayed loss of fitness in bloodstream form cells after 3
and 6 days induction. However, in addition to the dual RNAi OPB/OPB-like cell line, we gener-
ated an RNAi cell line in which the OPB-like gene alone was targeted, which displayed no
growth defect up to 4 days (data not shown). Altogether, a comparison of the two experiments
illustrates the necessity of following up large-scale RNAi screens with independent validation
of potentially interesting targets.
The S9 serine peptidases OPB and POP have been promoted as suitable drug targets [32]
based on their presence in the host bloodstream, and their ability to cleave host peptides. How-
ever, these peptidases are not essential for parasite survival, at least in vitro. T. brucei OPB
knockout parasites are viable and as virulent as wild-type parasites [25]. Similarly, T.cruzi and
L.major OPB null parasites are viable, albeit compromised in their ability to infect host cells
[3, 29]. By generating paired OPB and OPB-like RNAi knock-downs, we provide supporting
evidence that OPB is non-essential, but also show that the related OPB-like gene is most likely
not essential and that, if these two genes have an overlapping function, it is insensitive to
down-regulation at the levels achieved in this screen. We have also found no evidence that
OPB or POP influence parasite survival in host mice, so while they may be capable of cleaving
host cell peptides, this capacity does not alter the course of infection.
SPP1 was the only serine peptidase in T. brucei demonstrated to be essential for parasite sur-
vival. Type-I signal peptidases have been shown to be essential in all bacterial species examined
to date [13], and in yeast [33]. In Leishmania major, SPP1 null mutants could not be generated,
suggesting an essential function, and heterozygote mutants showed reduced infectivity [22].
Plasmodium falciparum dsRNA targeting type-I signal peptidase inhibited cell growth [29].
There is a high degree of conservation amongst type-I signal peptidase substrates, with the core
A-X-A motif recognised by eukaryotic ER and bacterial type-I signal peptidases [34]. This sub-
strate conservation is illustrated by the in vitro cleavage of E. coliMBP signal sequence by SPP1
from Plasmodium falciparum [29]. Type-I signal peptidases are not inhibited by standard ser-
ine protease inhibitors, and much work has gone in to developing signal peptidase inhibitors as
broad spectrum anti-bacterials [19]. The SPP1 inhibitor arylomysin and its derivatives are ef-
fective against some but not all bacteria, a spectrum which is limited by natural mutations in
SPP1 [35]. The effectiveness of arylomicin inhibitors on eukaryotic SPP1 is, to our knowledge,
not known. As broad spectrum efficacy is not required for treatment of HAT, screening these
S26A peptidase inhibitors against T. brucei would be an advisable approach.
We were able to show that T. brucei SPP1 is an active serine peptidase, and that this activity
is essential for parasite survival. The failure to detect activity in recombinant SPP1 forms may
be due to the absence of other signal peptidase complex subunits. A multi-subunit signal pepti-
dase complex (SPC) is probably present in T. brucei, as other eukaryotic type-I signal pepti-
dases are complexed with three other non-catalytic subunits [32]. We searched for similar
non-catalytic signal peptidase complex subunits in T. brucei by carrying out BLASTP searches
with yeast signal peptidase complex subunits against the T. brucei genome and retrieved one
SPC3-like subunit (Tb927.5.1930). The SPC3 subunit is essential for the activity of the catalytic
subunit (Sec11p) in yeast [36]. RIT-seq experiments indicate the T. brucei SPC-3 like subunit is
essential [6], so it may be worth investigating this gene more closely to clarify whether it is an
essential non-catalytic component of a T. brucei signal peptidase complex.
It is worth considering whether suitable SPP1 substrates are present in T. brucei. The cleav-
age motif for type-I signal peptidases (A-X-A) is well conserved across species, but the signal
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peptide also comprises a charged n-region and a hydrophobic h-region [34]. A search of the T.
brucei genome for coding sequences containing a signal peptide (using SignalP) and an A-X-A
motif within amino acids 22–32 found 230 genes (excluding pseudogenes) (S3 Table). It will be
interesting to examine the processing and localisation of some of these potential SPP1 sub-
strates within the SPP1 RNAi cell line. On the basis of our data, a significant defect in ER transit
would be predicted for many of these potential substrates.
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